Back to search

Peptide record

TPDB09022

Antibacterial Anticancer Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09022
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 pep-lab Peptipedia CancerPPD 2.0
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, pep-lab, Peptipedia, and other sources, with an available 3D structural model.
Sequence
KWCFRVCYRGICYRRCRG
Physicochemical Analysis
C101H157N35O21S4
ANDEQHLMPST
R
2325.82
10.10
6
0
6
+6
-1.00
-0.511
37.78
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
8730
375.35
6
Residue Composition
number
0
A
5
R
0
N
0
D
4
C
0
E
0
Q
2
G
0
H
1
I
0
L
1
K
0
M
1
F
0
P
0
S
0
T
1
W
2
Y
1
V
Amino Acid Distribution
A: 0 R: 5 N: 0 D: 0 C: 4 E: 0 Q: 0 G: 2 H: 0 I: 1 L: 0 K: 1 M: 0 F: 1 P: 0 S: 0 T: 0 W: 1 Y: 2 V: 1
Chemical Descriptors
18
C101H157N35O21S4
2325.82
10.10
+6
-1.00
-0.511
Evidence Records 3 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
106.9±21.0 µM
Hemolytic Cytotoxic
50% Hemolysis | 106.9±21.0 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties. | Int J Mol Sci | 2019
Evidence 2 Activity

Activity

50% Cell death
Toxicity
7.9±0.5 µM
Cytotoxic
50% Cell death | 7.9±0.5 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties. | Int J Mol Sci | 2019
Evidence 3 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs: CC50=107±21 µM | Cytotoxicity: HaCaT: CC50=7.9±0.5 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
ACS Chem Biol. 2019 Dec 20 14(12):2895-2908.